Novartis gets EU approval for potential blockbuster cholesterol drug Leqvio

Novartis said on Friday it received approval from the European Commission for Leqvio, also known as inclisiran, a drug to lower cholesterol that the Swiss drugmaker bought last year in a deal worth nearly $10 billion and expects to be a top seller.

from bdnews24.com - Home https://ift.tt/376dALT